Pharmaceuticals Trio Draw Buy Ratings Ahead of 2026 Catalysts
A trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
Reinforcing budgeting discipline involves regular reviews, automated savings, and mindful spending. Build confidence by sticking to small, repeatable actions.
17,282 articlesA trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
Investors weigh Amazon's Zoox-related progress against UPS's strategic shifts while oil volatility stirs the market. ...
Oracle is reshaping its business from database software to a cloud infrastructure powerhouse, fueled by surging backl...
A public clash between a legendary director and a veteran actor isn’t just drama. It’s a window into how money, reput...
Long-term investors are always asking which growth stocks hold next decade potential. This guide spotlights two prove...
Lucid Group has ambitious plans, but shifting from carmaker to tech supplier brings new risks. This article explains ...
The Midwest is driving the national housing surge, with absorption outpacing supply. Detroit, Chicago and Cleveland s...
Constellation Energy plunged today after a mix of macro moves and strategic shifts. This guide breaks down the factor...
A new forecast warns that a 60-day Iran clash could push the federal deficit higher by about $65 billion, on top of t...
Hajime Construction enlarges its U.S. footprint by acquiring a 51% stake in Wright Homes of Utah, gaining management ...
Rising energy costs are pushing fertilizer prices higher, with the potential to lift grocery bills in the coming mont...
Wedbush boosts its Micron price target to $500, arguing demand remains healthy after the Chinese New Year. The upgrad...